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Available online 20 December 2018Introduction: Therapeutic options for diffuse malignant peritoneal mesothelioma (DMPM) are limited to surgery
and locoregional chemotherapy. Despite improvements in survival rates, patients eventually succumb to disease
progression.We investigated splicing deregulation both asmolecular prognostic factor and potential novel target
in DMPM, while we tested modulators of SF3b complex for antitumor activity.
Methods: Tissue-microarrays of 64 DMPM specimens were subjected to immunohistochemical assessment of
SF3B1 expression and correlation to clinical outcome. Two primary cell cultures were used for gene expression
proﬁling and in vitro screening of SF3b modulators. Drug-induced splicing alterations affecting downstream cel-
lular pathways were detected through RNA sequencing. Ultimately, we established bioluminescent orthotopic
mouse models to test the efﬁcacy of splicing modulation in vivo.
Results: Spliceosomal genes are differentially upregulated in DMPM cells compared to normal tissues and high
expression of SF3B1 correlated with poor clinical outcome in univariate and multivariate analysis. SF3bmodula-
tors (Pladienolide-B, E7107,Meayamycin-B) showed potent cytotoxic activity in vitrowith IC50 values in the low
nanomolar range. Differential splicing analysis of Pladienolide-B-treated cells revealed abundant alterations of
transcripts involved in cell cycle, apoptosis and other oncogenic pathways. This was validated by RT-PCR and
functional assays. E7107 demonstrated remarkable in vivo antitumor efﬁcacy, with signiﬁcant improvement of
survival rates compared to vehicle-treated controls.
Conclusions: SF3B1 emerged as a novel potential prognostic factor in DMPM. Splicing modulators markedly im-
pair cancer cell viability, resulting also in potent antitumor activity in vivo. Our data designate splicing as a prom-
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Malignant mesothelioma (MM) is a rare neoplasm of the lining of
the pleural, peritoneal and pericardial cavity, as well as tunica vaginalis.
Diffuse malignant peritoneal mesothelioma (DMPM) accounts for
10–30% of all cases of mesotheliomas, and its incidence is increasing
worldwide [1]. This tumor is usually difﬁcult to diagnose, both clinically
and histologically, and is characterized by poor prognosis. Systemic
chemotherapy is rarely effective [2], and cytoreductive surgery (CRS)
combined with hyperthermic intraperitoneal chemotherapy (HIPEC)
has become the new standard of care for selected patients. This treat-
ment has improved survival (median OS of ~100 months), however,
many patients still suffer of disease recurrence, especially when CRS
fails to remove tumors from inaccessible abdominal loci [3]. Thus,
novel therapeutic options to implement in the current surgical and
HIPEC procedures are warranted.
Genomic studies were conducted on DMPM subsets by array-CGH,
FISH and targeted DNA sequencing with the ultimate goal of ﬁnding
new molecular targets. These studies reported that genetic alterations
commonly found in pleural mesothelioma (BAP1, NF2, TP53 and
CDKN2Amutations and/or copy number alterations) were also present
in DMPM, although their frequencies vary according to the anatomical
localization [4–6].
Recently, Bueno and collaborators carried out an extensive exome
sequencing of a large collection of pleural mesothelioma specimens
[7]. Besides the aforementioned MM-speciﬁc alterations, this study re-
ported mutations affecting splicing factor 3b subunit 1 (SF3B1), which
encodes an essential component of the spliceosome, as well as the his-
tone methyltransferase SETD2 and the DEAD-box RNA helicases
DDX51 and DDX3X, which are also involved in RNA processing and
splicing. In addition, these analyses unraveled several MM-speciﬁc
splice alterations, most of which were independent of splice site muta-
tions. Collectively, thesedata highlight epigenetic and splicingderegula-
tions as important features of MM pathogenesis and suggest their
exploitation as novel antitumor strategy.
Alternative splicing (AS) is the essential process in eukaryotic gene
expression by which non-coding intron sequences are removed from
the pre-mRNA transcripts and speciﬁc exons are included or excluded
from mature mRNAs. AS is controlled by a number of splicing factors
(SFs) which recognize regulatory pre-mRNA sequences, assemble as a
multi-protein complex called “spliceosome” and catalyze the reaction
in a stepwise fashion. Multiple transcripts generated from a single
gene can be translated into proteins, often executing distinct functions.
Defects in splice factor genes, such as changes in expression levels
or mutations, can produce aberrant mRNA splicing patterns on a
genome-wide scale. This was demonstrated to be common in several
cancers, mostly hematological malignancies [8].
Interestingly, these alterations have also prognostic signiﬁcance [9]
and contribute signiﬁcantly to all hallmarks of tumorigenesis [10].
Therefore, splicing deregulation could represent a novel susceptibility
to be explored for cancer therapy.
Pharmacological modulation of spliceosome activity via small mole-
cules has shown potential in several pre-clinical studies [11]. FR901464,
GEX1A and pladienolides are natural antitumormolecules targeting the
SF3b complex. These compounds showed cytotoxic activity in the low
nanomolar range in several tumor cell lines and reduction of tumor bur-
den in vivo, which led to the synthesis of improved analogues such as
meayamycins, spliceostatins and sudemycins [12–14].
The administration of E7107, a pladienolide derivative, in a Phase 1
trial stabilized the disease in 8 out of 40 cancer patients and reached
partial response in one subject affected by metastatic pancreatic cancer
[15]. Inhibition of splicing was observed during dose escalation, and
the dose-limiting toxicity was primarily gastrointestinal related; how-
ever, visual impairment was reported in 2 patients [16]. A next genera-
tion splicing modulator, H3B-8800, is now in Phase 1 clinical trial
(NCT02841540) [17].Herewe investigate for the ﬁrst time the rationale of splicing as new
target in DMPM by analyzing the expression of splice factors in patient
tissues and correlating them with clinical outcome. Furthermore, we
tested the antitumor effects of SF3b modulators in primary DMPM cell
cultures and analyzed global changes in splicing patterns through RNA
sequencing in vitro. Finally, we have established a unique orthotopic
DMPM mouse model to monitor the efﬁcacy of E7107 in vivo through
innovative imaging techniques.
2. Materials and methods
2.1. Cell lines and culture conditions
Human epithelioid DMPM primary cultures (MesoII and STO) were
derived from tumor samples of patients who underwent surgery [18]
and maintained in DMEM/F12 in standard culturing conditions for b20
passages. Cells were routinely tested for mycoplasma at Microbiome
(Amsterdam, the Netherlands) and resulted free of contamination.
MesoII cells bear a SF3B1 heterozygous mutation (A1279S) which ap-
pears to be conserved and benign, according to several pathogenicity
scores from the dbNSFP database (Supplementary Table 1). Co-
transduction of cells with Fm and GC vectors and F-luc activity assess-
ment were performed according to previously established methods
[19–21].
2.2. Splicing modulators
Meayamycin-B (MAMB) was kindly provided by Prof. K. Koide
(University of Pittsburgh). Pladienolide-B (PB) was purchased from
Cayman Chemical (AnnArbor,MI, USA). E7107was provided byH3Bio-
medicine (Cambridge, MA, USA).
2.3. RNAi and cell viability assessment
RNAi experiments were performed by using siRNA duplexes
from the Dharmacon (Lafayette, CO, USA) SMARTpool siGENOME
controls targeting UBB (M-013382-01) and NTp2 (D-001206-14) or
two siGENOME siRNAs targeting SF3B1 (D-020061-07-0002 and
D-020061-05-0002). Viability after transfection was measured with
CellTiter-Blue reagent (Promega, Leiden, the Netherlands). Cell viability




2.4. Cell cycle, apoptosis and proliferation assay
For the proliferation and apoptosis assay, cells were stained with 7-
AAD (Via-Probe™, BD Bioscience, san Jose, CA, USA). To determine apo-
ptosis, 7-AAD-stained cells were incubated with FITC-labeled AnnexinV
antibody (Apoptest™, VPS Diagnostic, Hoeven, the Netherlands) in 5×
diluted Annexin binding buffer (Invitrogen/ThermoFisher Scientiﬁc, Or-
egon, USA). Absolute cell count for proliferation assay was obtained by
using Flow-Count™ Fluorospheres (Beckman Coulter, CA, USA).
For cell cycle analysis, ethanol-permeabilized cells were incubated
with RNAse A (100 μg/ml, QIAgen, Venlo, the Netherlands) and stained
with propidium iodide (Sigma-Aldrich). In all assays ﬂuorescence was
measured using BD LSRFortessa and data analysis performed with
FACS Diva software version 8.0.1.1 (BD Bioscience).
2.5. Wound healing assay
Cells were seeded in 96-well plates 24 h before the assay (MesoII:
3*104 cells/well; STO: 6*104 cells/well), wound tracks were made with
a 96-pin scratcher and the cells were subsequently cultured for 24 h
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tion). Images were taken immediately after the scratch and after 24 h
of drug exposure with a Leica DMI300B migration station (Leica
Microsystems, Eindhoven, the Netherlands) and analyzed with the
Scratch Assay 6.2 software (Digital Cell Imaging Labs, Keerbergen,
Belgium).
2.6. Spheroid aggregation assay
Spheroids with a diameter of approximately 300 μmwere created
in 96-well ﬂat bottom plates coated with 1.5% agarose. DMEM/F12
medium was replaced with drug-free medium or medium contain-
ing 30 nM PB (6 wells per condition) every two or three days for
11 days. Images of spheroids were taken with an automated phase-
contrast microscope (Universal Grab software, Digital Cell Imaging
Labs).
To detect the amount of light passing through the spheroids, pixel
intensities of 8-bit black/white-converted images were calculated
using ImageJ Software (U.S. National Institutes of Health, Bethesda,
Maryland, USA) and expressed as Mean Gray value (= sum of all
Gray values of the spheroid selection divided by the pixels of that se-
lection). Inhibition of cell aggregation for each drug-treated spheroid
at Day 9 (“treated” in the formula below) was calculated by normaliz-
ing for the Mean Gray values of the sum control spheroids (“∑ con-
trol”, where “n” is the number of replicates in the formula below) as
follows:






2.7. Gene expression analysis of DMPM cells
Transcriptomic data from MesoII and STO cell lines and 3 normal
mesothelium tissues were generated using Illumina HumanHT-12 v4
arrays. We are aware of the limitation of comparing normal mesothe-
lium tissues with primary cells. However our primary cells were ana-
lyzed at their ﬁrst passages, and retained the main features of the
originator tumors. Raw data were log2-transformed and normalized
using the lumi package [23], then ﬁltered and annotated. Raw and nor-
malized data were deposited at Gene Expression Omnibus (accession
number: GSE112154).
Differential gene expression was estimated using the limma
Bioconductor package [24] in R environment. A t-value pre-ranked
gene set enrichment analysis (GSEA; http://software.broadinstitute.
org/gsea/index.jsp) was carried out using GO Biological Process
ontology (c5.bp.v6.1) and KEGG common pathway (c2.cp.kegg.v6.1)
gene sets of the Molecular Signature database (MSigDB). The Normal-
ized Enrichment Score (NES) was used to measure the gene-sets
enrichment.
2.8. RNA sequencing
Total RNA from cells and freshly frozen orthotopic tumor tissues
was extracted with RNeasy mini Kit (QIAgen). RNA integrity was
assessed with RNA 6000 Nano Kit on a 2100 Bioanalyzer system
(Agilent Technologies Inc., Santa Clara, CA, USA). Sequencing libraries
were prepared with the Illumina TruSeq Stranded mRNA Library Prep
LT Kit (RS-122-2201, Illumina Inc., San Diego, CA, USA) and Agencount
AMPure XP beads (Beckman Coulter). cDNA library size and concentra-
tion was measured by Bioanalyzer. Single-end, 100 bp-reads were ob-
tained from Illumina RAPID Chip on HiSeq 2500 System (Illumina).
The sequencing reaction yielded 40.1 ± 7.3 (average ± SD) million
passing-ﬁlter raw reads/sample. Bioinformatic pipeline for data analy-
sis is described here [22]. rMATS version 3.2.5 was used to detect
unique AS events (ES, A5SS, A3SS and RI, with the exception ofmutually exclusive exons) with FDR b 0.01, which were imported to
Excel. The events were additionally ﬁltered based on the sum of inclu-
sion and skipping counts by using the median value of total counts
(N350) as the cut-off value. Events below that value were discarded
as supported by insufﬁcient counts. Filtered AS events are collected in
Supplementary Table 2 and raw AS events are collected in Supplemen-
tary Table 5. Z-score and hierarchical clustering of inclusion levels (Ψ)
of AS events were calculated and visualized by using Perseus software
[25].
Gene expression estimates from orthotopic tumor samples and pa-
rental cell line samples were calculated with EdgeR and visualized by
ggplot, both R software from Bioconductor repository. Differential
gene expression data of DMPM cells after treatment with PB are re-
ported in Supplementary Table 3.
gProﬁler version r1741_e90_eg37 (https://biit.cs.ut.ee/gproﬁler/
index.cgi) [26] was used for pathway analysis of genes affected by AS
and selecting GO, KEGG and REACTOME databases (Supplementary
Table 2). AS events were visualized as sashimi plots with IGV genome
browser, http://software.broadinstitute.org/software/igv/home). cDNA








RNApolymerase I D_ex1_Fw (5′-TGGAAGAGGATCAGGAGCTGG-3′).
RNApolymerase I D_ex2_Rev (5′-CATGAGCTCATTCAGGCCTCTC-3′).
BclX_ex2F (5′-GGGCATTCAGTGACCTGACA-3′).
BclX_ex3R (5′-GGGAGGGTAGAGTGGATGGT-3′).
2.9. Orthotopic mouse model and live imaging
Nu/nu female mice were purchased from Harlan Laboratories
(Madison, WI, USA). Animal experiments were performed in accor-
dance with the European Community Council Directive 2010/63/EU
for laboratory animal care and the Dutch Law on animal experimen-
tation. The working protocol was validated and approved by the
local committee on animal experimentation of the VU University
Medical Center (DEC HEMA14–01). At day 0, tumors were induced
by injection of 2*106 fm/GC cells in the peritoneal cavity of the
mice.
Bioluminescence imaging (BLI) was performed with a Bruker In-
Vivo Xtreme Capture System and data was analyzed using Molecular
Imaging Software (Bruker Corporation, Billerica, Massachusetts,
USA). Mice were selected for PET-MRI and PET-CT on the basis of
the intensity of the BLI signal. G-luc levels from plasma samples
were measured with a luminometer immediately after adding
25 mg/ml coelenterazine (Alfa Aesar, Haverhill, MA, USA) as substrate.
[18F]-FDG was produced routinely by BV Cyclotron VU (Amsterdam,
The Netherlands) with a radiochemical purity of N97% and adminis-
tered via intraocular injection (5 MBq/mouse). PET-CT and PET-MRI
were performed with nanoPET-CT and nanoPET-MRI (Mediso, Buda-
pest, Hungary). For PET-CT, a computed tomography (CT) scan was
performed for 5 min, followed by tracer administration at the start
of a dynamic PET scan of 60 min. For PET-MRI (ﬁeld strength =
1 T), T1- and T2-weighed images were acquired for one hour after
tracer administration.
PET data were normalized, and corrected for scatter, randomization,
attenuation, decay and dead time. List-mode PET datawere re-binned in
19 successive frames (4 × 5 s, 4 × 10s, 2 × 30s, 3 × 60s, 2 × 300 s, 3
× 600 s and 1 × 900 s), which were reconstructed using an iterative
3D Poisson ordered-subsets expectation maximization algorithm with
four iterations and six subsets. Resulting images had a matrix size of
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Data were normalized and images analyzed as previously described
[27].
2.10. Patient material and tissue microarray (TMA) construction and im-
munohistochemistry (IHC)
Tumor tissues of 64 DMPM patients treated with CRS and HIPEC in
the National Cancer Institute of Milan (from August 1995 to October
2013) were selected for pathological examination. Normal mesothe-
lium tissueswere obtained from surgeries of patients affected by benign
familiar adenomatous polyposis. TMAswere constructed as described in
[28] by using a tissue-arraying instrument (Beecher Instruments, Silver
Springs, MD, USA). Monoclonal SF3B1 antibody (Cat. D221–3) was pur-
chased from MBL, Medical & Biological Laboratories CO. LTD. (Japan).
2.11. Statistical analysis and graphs
Clinical outcome was correlated with N-stage, histological subtype,
performance status, cytoreduction and SF3B1 expression by means of
a univariate analysis using a Mantel-Cox (Log rank, Chi-Square) test.
Survival rates were calculated using the Kaplan-Meier method.
Amultivariatemodel to assess the prognostic relevance of SF3B1 ex-
pression was obtained by selecting independent prognostic factors
among all clinical and surgical parameters (selected as covariates) and
using the backward stepwise elimination (Wald) method.
Statistical analysis for clinical data was performed with SPSS version
22 (IBM Corporation, NY, USA). Graphs and statistical analysis for in-
vitro experiments were produced with GraphPad Prism version 6.
3. Results
3.1. Splicing factors are upregulated in DMPM and SF3B1 expression is an
independent prognostic factor
In search for potential therapeutic targets, we performed gene ex-
pression proﬁling between two primary epithelioid DMPM cell cultures,
namely MesoII and STO [29], and three normal mesothelium tissues,
which resulted in a total of 4042 genes differentially expressed, of
which 2217 up-regulated and 1825 down-regulated in the DMPM cells.
Pathways involved in RNA splicing and spliceosome complex assem-
bly were overrepresented among genes up-regulated in DMPM cells, as
revealed by gene set enrichment analysis (GSEA, Fig. 1A). In particular,
MesoII and STO cells express higher mRNA levels of members of the
SF3b family and U2AF2 compared to normal tissues (Fig. 1B). These
genes encode for splicing factorswhich recognize pre-mRNA transcripts
and assist the recruitment of the spliceosome machinery to regulatory
sequences (Fig. 1C).
We then investigated whether the expression levels of SF3B1 pro-
tein correlate with the treatment outcome of DMPM patients. To this
end, we determined SF3B1 expression by tissue microarrays (TMAs)
performed on histological specimens of 64 DMPM patients (Fig. 1E
and Supplementary S1A).
The expression levels of SF3B1 protein varied among specimens and
patients were categorized according to their SF3B1 levels using a 6-
grade scoring system described in Fig. 1D and Supplementary Fig. S1B.
The univariate Cox regression analysis revealed a signiﬁcant correlation
between high SF3B1 level and shorter overall and progression-free sur-
vival (Fig. 1F). Importantly, multivariate analysis, including well-
established predictors of the treatment outcome in DMPM, conﬁrmed
the independent prognostic value of SF3B1 (Fig. 1E).
Altogether, these data demonstrate that DMPM is characterized by
elevated expression of splicing factors and that high level of SF3B1 pro-
tein is associated with inferior treatment outcome. Therefore, targeting
SF3b complex in these patients could constitute an attractive therapeu-
tic option.3.2. Splicing modulators targeting SF3b complex induce DMPM cell death
To address this hypothesis, we tested the effects of threemodulators
of SF3b complex activity (Pladienolide-B, E7107 and Meayamycin-B,
depicted in Fig. 2B) on the viability of MesoII and STO cells. Remarkably,
both primary cell cultures were extremely sensitive to all spliceosome
modulators with IC50 values within low nanomolar ranges (Fig. 2A).
Of note, siRNA-mediated knockdown of SF3B1 drastically decreased
cell viability compared to non-targeting control, thus underlining the
key role of SF3B1 in cell viability (Fig. 2C).
3.3. Pladienolide-B induces splicing alterations in relevant cellular
pathways
To investigate the downstream effects of spliceosome modulation,
we performed high-throughput sequencing of total mRNA of MesoII
and STO cells treated with 30 nM Pladienolide-B (PB, Fig. 3A). A 4-h ex-
posure time was sufﬁcient to induce intron retention of the DNAJB1
transcript, known to be affected by PB [14](Supplementary Fig. S2). Dif-
ferential splicing analysis between untreated and PB-treated samples
detected 2804 signiﬁcant AS events, predominantly skipped exons
(ES) and retained introns (RI, Supplementary Fig. S3), which affected
1304 genes. The magnitude of each AS event is expressed as inclusion
level (or Percentage Spliced In, Ψ, [30]), measured by comparing un-
treated and PB-treated samples and visualized as a heat-map in Fig. 3B.
Pathway analysis performed onAS events revealed several processes
involved in regulation of gene expression (e.g. splicing, ribosome bio-
genesis/translation and protein degradation by proteasome), cell prolif-
eration and survival, cell cycle control, response to stress and apoptosis
(Fig. 3C-D).
Interestingly, among PB-induced AS events we found transcripts
encoding kinases with tumorigenic functions in MM [31] such as
AKT1, RAF1, MAP2K1 and ABL1 (Supplementary Table 4). Collectively,
our results demonstrate that PB treatment perturbs the global splicing
landscape of DMPM cells and affects genes essential for disease patho-
genesis and survival of malignant cells.
3.4. Splicing modulation affects essential cellular functions in DMPM
Oneof the best documented effects of spliceosomemodulation is the
skipping of exon 2 of the apoptotic geneMCL-1 which is translated into
a truncated protein isoform exhibiting pro-apoptotic functions [32]. Ac-
cordingly, MCL-1/S (short) variant was induced in DMPM cells after 24-
h PB exposure in both MesoII and STO cells, reaching its highest peak at
30 nM (Fig. 4A). Similarly, the transcript of the apoptotic gene BCL-X
was converted into its pro-apoptotic splice variant (BCL-X/S) upon PB
exposure, although this effect seems to be less prominent at high drug
concentrations (Supplementary Fig. S4). This suggests some functional
redundancy between apoptosis regulators.
Concomitant with the altered splicing of these apoptotic regulators,
the percentage of apoptotic cells (AnnexinV-positive) increased signiﬁ-
cantly upon 48-h PB treatment. Apoptosis induction in MesoII and STO
cells was dose-dependent and reached 35% and 81% respectively
(Fig. 4B). In addition,we observed a block inG1 andG2 phase and a con-
comitant reduction of cells in the S phase (Fig. 4C). These data con-
ﬁrmed that cell cycle progression is heavily affected by spliceosome
modulation, as reported in previous studies [13] and provokes a drastic
reduction of cell proliferation (Supplementary Fig. S5).
Migration processes are also inﬂuenced by alternative splicing [33].
In particular, we found that MesoII and STO cells express the truncated
variant of the proto-oncogene RON (Fig. 4A). ΔRON plays a pivotal role
in cancer cell motility due to its constantly activated kinase function
[34] and might underlie the typical expansive growth pattern of
DMPM [1]. Interestingly, a 24-h exposure to 10 and 30 nMPB caused in-
tron retention in RON transcript and decrease in transcript abundance,
which is probably due to nonsense-mediated decay (NMD) of the
Fig. 1. Core spliceosomal genes are upregulated in DMPM cells and SF3B1 is an independent predictor of the treatment outcome. (A) Scatter plot showing normalized enrichment score
(NES) and relative signiﬁcance (FDR) of both GO and KEGG pathways in DMPM cell lines compared to normal specimens, as from GSEA. In the magniﬁcation, dots referred to splicing-
related pathways are bordered in black. (B) Box plots reporting gene expression values of 4 selected splicing factors in DMPM cells and normal mesothelium samples. (C) Schematic
representation of cis-acting elements orchestrating the pre-mRNA splicing reaction and early spliceosome assembly (Complex A). A typical pre-mRNA is composed of exonic
sequences (blue boxes) interspaced by intronic regions (thin black line) which are deﬁned by 5′ and 3′ splice sites (5`SS and 3`SS) and two additional regulatory consensus sequences
(BPS: branchpoint sequence; Poly-Y: polypyrimidine tract). The process of splicing results in the junction of adjacent exonic sequences by two subsequent trans-esteriﬁcation
reactions and the removal of the intron in the form of a lariat. The splicing reaction is catalyzed by splice factor proteins (SF and SRSF), small nuclear ribonucleoproteins (snRNP) and
auxiliary factor proteins (AF), which interact by forming dynamic complexes with the pre-mRNA. For simplicity, only Complex A is shown here. U1 snRNP binds to the 5`SS via base-
pairing interactions between small nuclear RNA (snRNA) and pre-mRNA; auxiliary U2AF2 and U2AF1 factors bind to the Poly-Y tract and to the 3`SS respectively; U2 snRNP binds to
the BPS and base-pairing interactions are stabilized by SF3b complex. SF3B1 and PHFA5 (SF3B14), in particular, make contact with the “invariant” adenine of the BPS (“A”), which
initiates the ﬁrst transesteriﬁcation reaction [51] [52]. (D) Representative pictures of TMA cores (original magniﬁcation 20×) obtained from parafﬁn-embedded DMPM specimens. The
ﬁgure illustrates the scoring system used to assess SF3B1 protein expression upon incubation with an anti-SF3B1 speciﬁc antibody, as described in the methods. (E) Clinicopathologic
characteristics and SF3B1 protein expression in relation to the treatment outcome (overall survival – OS; progression-free survival – PFS) in DMPM patients. The results of univariate
and multivariate Cox regression analysis are shown. * There were 56 deaths (event rate of 93.3%), while four patients were lost at follow-up after disease progression at last contact.
The percentages for each clinicopathological characteristic are calculated according to these data. ** Data on Ki-67 index, subtyping and N-stage were not available for 7, 3 and 4 cases,
respectively. (F) Kaplan-Meier analysis of SF3B1 protein expression in relation to OS and PFS in DMPM patients. P-values were determined with the Log-rank (Mantel-Cox) test.
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tary Table 5). To assess the functional effects of RON mis-splicing, we
performed a 24-hwound-healing assay andwe showed that incubation
with PB resulted in a statistically signiﬁcant inhibition of cell migration
compared to untreated controls (Fig. 4D), consistent with the observed
splicing modulation of RON. This effect was more pronounced in STO
cells, which express higher levels of the ΔRON variant compared to its
wild type transcript.Ultimately, spliceosome modulation affects pathways controlling
focal adhesions (Fig. 3D and Supplementary Fig. S7). To investigate the
effects of the drug on cells organized in tridimensional structures, we
imaged DMPM-derived spheroids exposed to 30 nM PB (Fig. 4E). Un-
treated spheres appear compact and dense, while treated ones appear
more loose, especially at the outer layers, indicating progressive deteri-
oration of cell-cell interactions. Inhibition of cell-cell aggregation was
measured by detecting the amount of light passing through the
Fig. 2. Splicing modulators induce DMPM cell death through SF3b-speciﬁc modulation. (A) Dose-dependent inhibition of cell growth by Pladienolide-B (PB), E7107 and Meayamycin-B
(MAMB) in two DMPM primary cell lines (MesoII and STO). Cell viability was determined using SRB assay upon 72 h treatment with increasing concentrations of splicing modulators.
Data points represent mean percentage of cell growth relative to untreated cells ± SD of three independent experiments. IC50 values ± SD (drug concentration that inhibits 50% of
cell growth) were determined by graphical interpolation of dose-response curves and reported as follows: 1.57 ± 0.29 nM and 0.82 ± 0.1 nM for PB, 1.27 ± 0.04 nM and 0.34 ±
0.08 nM for E7107, 1.19 ± 0.43 nM and 1.00 ± 0.3 nM for MAMB, in MesoII and STO cells respectively. (B) Chemical structures of PB, E7107 and MAMB and schematic representation
of their targets SF3B1 and PHF5A. The molecules destabilize U2 snRNP assembly at the interface between BPS, U2 snRNA and SF3b complex [13]. (C) Cell viability 5 days after
transfection with two siRNAs targeting SF3B1 (siSF3B1–07 and siSF3B1–05) compared to non-targeting control siRNA (siNTp2, set to 1) and a positive control (siUBB). Data are
derived from two independent experiments. Asterisks indicate statistical signiﬁcance compared with siNTp2 (****P b 0.0001, ***P b 0.001, **P b 0.01 Student's t-test).
220 R. Sciarrillo et al. / EBioMedicine 39 (2019) 215–225spheroids (see Methods). PB-treated spheres show 2- to 3-fold higher
inhibition levels compared to untreated controls (Fig. 4E).
Altogether, these data indicate that splicing modulation in vitro af-
fectsmolecular processes involved in cell migration, cell-cell interaction
and cell cycle progression which ultimately lead to apoptosis. Conse-
quently,we evaluated the antitumor efﬁcacy of SF3b-modulating agents
in vivo.
3.5. Establishment of in vivo orthotopic DMPM mouse models
We ﬁrst developed two novel bioluminescent (BLI) orthotopic
mouse models in order to monitor the tumor growth over time. MesoII
and STO cells were co-transducedwith two lentiviral vectors expressing
Fireﬂy luciferase-mCherry (Fm) andGaussia luciferase-CFP (GC), as pre-
viously described [19–21]. Intensity of the BLI signal in vitrowas directly
proportional to the number of cells (Fig. 5A) and they successfully
engrafted in the peritoneal cavity of immune deﬁcient mice (100%
take rate). MesoII models showed superior transduction efﬁciency com-
pared to STO and were used in the following experiments.
To determine the spatial localization of the tumor masses, we per-
formed a rotational BLI analysis (MARS system - Supplementary Video
1). Moreover, BLI was complemented with PET-CT and MRI analyses
(Supplementary Video 2 and 3, respectively), performed 10 days after
cell implantation. DMPM-derived tumors were detectable in thewhole abdominal cavity as multiple nodules, thus reproducing the dif-
fusion pattern of the clinical disease (Fig. 5B).
After about 40 days, untreated mice manifested the typical symp-
toms of DMPM, such as jaundice and accumulation of ascitic ﬂuid in
the peritoneal cavity. Macroscopic analysis of animal tissues revealed
nodules in close proximity of the gastrointestinal tract, as previously re-
ported [6,18](Fig. 5C). These lesions interferedwith digestive processes,
thus causing gallbladder enlargement and cachexia. To investigate
whether our mouse models recapitulate the histopathology and geno-
mic proﬁles of human DMPM, we performed both IHC and RNA-
sequencing analyses. DMPM xenografts were comparable to surgical
material resected from the human originator tumors and maintained
high SF3B1 protein expression (Fig. 5C).
3.6. Anti-tumor activity of E7107 in DMPM xenografts
After stratiﬁcation of the mice into groups with comparable BLI sig-
nal, E7107 was administered intraperitoneally according to treatment
regime (Fig. 6A).
To avoid body weight loss potentially leading to discontinuation of
the study, the initial dose was halved after two consecutive injections
(Supplementary Fig. S8). BLI was monitored twice per week until day
50, then every 3 weeks. Starting already from Day 8, mean F-luc inten-
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Fig. 3. Transcriptome-wide (global) splicing changes induced by PB in DMPM. MesoII and STO cells were treated with 30 nM PB for 4 h, followed by RNA sequencing-based analysis of
global splicing. (A) Schematic workﬂow, including differential splicing analysis of RNA sequencing data (using rMATS) and its output. Total number of signiﬁcant AS events and the
affected genes are shown. AS events were considered signiﬁcant when FDR b 0.01 and total supporting read counts (sum of counts in all the analyzed samples supporting both
inclusion and skipping) per splicing event were above 350 (median value). (B) Hierarchical clustering based on inclusion levels (or Percentage Spliced In, Ψ) of signiﬁcant splicing
events calculated by rMATS and Z-score-normalized. (C)Major biological processes affected by PB-induced AS events as determined by gProﬁler [26]. Gray bars represent the enrichment
score per each term (P b 0.05) expressed as Enrichment of Query genes per Term (Q&T/T). (D) Sashimi plots depicting PB-induced splicing alterations in selected genes involved in cell
cycle (CCNA2, CHEK1) and apoptosis regulation (HSPH1, DDX3X). IGV plots were set to same scale for all samples. For PB-treated samples, the number of junction reads connecting the
leftmost directly to the rightmost exons are higher than the ones connecting to the central exon, indicating increase in ES.
221R. Sciarrillo et al. / EBioMedicine 39 (2019) 215–225as compared to untreated control mice (Fig. 6B and C). Importantly, the
measurement of G-luc intensities in blood paralleled F-luc read out (i.e.
G-luc intensity in the treatment group was 180-fold decreased com-
pared to the control group at day 43, Supplementary Fig. S9).
In addition, RT-PCR of tumor samples frommice showed that E7107
treatment altered the splicing proﬁles of the same genes affected by PB
and E7107 exposure in vitro (Supplementary Fig. S10 and S11).
Tumor growth inhibition was reﬂected in a signiﬁcantly longer sur-
vival of treated mice. As illustrated by the Kaplan-Meier analysis in
Fig. 6D, animals in the E7107-treated group showed an increase in sur-
vival rate compared to vehicle-treated group (Pb 0.0001). Animals from
the control group were sacriﬁced according to humane end-point (ac-
cumulation of ascitic ﬂuid, cachexia, high tumor load and obstruction
of gastrointestinal tract) after approximately 50 days. Remarkably, at
the end of the experiment, three mice from the treatment group were
clear of tumor cells, while two mice died from disease progression and
one died from infection (no tumor masses were detected during post-
mortem examination).
4. Discussion
In this study for the ﬁrst time we demonstrate the high potential of
targeting the spliceosome in DMPM. Initially, we found that primary
DMPM cells show elevated expression of splice factor genes when com-
paredwithnormalmesothelium tissues. These ﬁndings extend previousstudies, showingup-regulation of SFswith pro-tumorigenic roles in sev-
eral neoplasms including lung, colon and breast cancer [9]. However,
different components of the splicing machinery may also act as a
tumor suppressor and controversial data on their prognostic role have
been reported in some tumor types. In particular, SF3B1 mutations
are associated with a favorable prognosis in patients affected by
myelodysplastic syndromes, in contrast to chronic lymphocytic leuke-
miawheremutated SF3B1 dictated a poor prognosis andwas associated
with ﬂudarabine resistance [10].
Interestingly, in our analysis performed on a large cohort of DMPM
patientswe found that the overexpression of SF3B1 protein is associated
with signiﬁcantly worse prognosis and is an independent risk factor of
both death and disease progression.
SF3B1 is the most commonly mutated spliceosomal gene,
both in hematological and solid cancers; mutations occur in 20% of
myelodysplastic syndromes [35] and above 22% of uveal melanoma
cases [36]. Darman and collaborators [37] showed that SF3B1 hotspot
mutations induce aberrant 3` splice site selection. This in turn results
in non-sense mediated decay for approximately 50% of the transcripts
as well as production of aberrant proteins in cancer cells. Based on cur-
rent data, we now speculate that not only mutations, but also the over-
expression of SF3B1 perturbs splicing catalysis and results in the
synthesis of pro-tumorigenic splice variants, which may constitute a
vulnerability of cancer cells. Splice-switching oligonucleotides and
RNA interference are suitable tools to target such variants in vitro [38],
Fig. 4. PB induces apoptosis and cell cycle arrest and impairs DMPM cell migration and aggregation which is associated with alternative splicing of several genes involved in these
processes. (A) Splicing proﬁles of MCL-1 and RON for MesoII and STO cells assessed by RT-PCR after 24 h incubation with 1, 10 and 30 nM PB. Schemes of pre-mRNA structures with
primer annealing sites (black triangles) and predicted PCR products are shown on the left. (B) PB-induced apoptosis in MesoII and STO cells treated at 1, 10 and 30 nM for 24 and
48 h. Cells were stained with 7AAD and AnnexinV-FITC and analyzed by ﬂow cytometry. Bars represent mean percentage of apoptotic (AnnexinV-positive) cells in each condition ±
SEM of three independent experiments. Asterisks indicate statistical signiﬁcance compared to untreated cells at 48 h (**P b 0.01, *P b 0.05, Student's t-test). (C) Cell cycle distribution
of cells stained with propidium iodide as measured by ﬂow cytometry at several time points (6, 24 and 48 h) after treatment with 1, 10 and 30 nM PB. Bars represent mean
percentages of cells in G0/G1, S and G2/M phases of at least two independent experiments (**P b 0.01, *P b 0.05, Student's t-test). (D) Wound healing assay performed for MesoII and
STO cells incubated with 15 and 30 nM PB for 24 h after creating wound tracks in 96 well plates. Bars represent mean wound area ± SEM of three independent experiments (at least
10 wells per condition in each experiment). Asterisks indicate statistical signiﬁcance compared to untreated cells at 24 h (****P b .0001, ***P = 0.001, *P = 0.05, Student's t-test).
(E) Inhibition of cell aggregation measured in spheroids after 9 days incubation with 30 nM PB. Bars on the left represent normalized mean gray values of digital pictures ± SD (N =
6, ****P b 0.0001, Student's t-test). Representative images of spheroids at Day 3 (start treatment) and Day 9 for both MesoII and STO cells are shown on the right.
222 R. Sciarrillo et al. / EBioMedicine 39 (2019) 215–225however it remains difﬁcult to use these agents in the clinical setting
due to limited stability in plasma and intracellular uptake [11].
Therefore we focused on small antitumor molecules targeting SF3b
complex based on the assumption that their activity would be
more clinically relevant in tumors where the expression of these fac-
tors is altered.
Two recent studies interrogating the molecular structure of U2
snRNP bound with PB and E7107 revealed that the conformation of
the SF3B1 catalytic pocket, in association with PHF5A, is critical for
BPS recognition and these compounds compete for the pre-mRNA sub-
strate in a dose-dependent fashion [39,40].
Next to thepotent in vitro antitumor activity of PB, E7107 andMAMB
in twoprimaryDMPMcultures,we also provide theﬁrst AS landscape of
DMPM, as result of the perturbation by SF3b modulation. The PB-
induced AS events affecting essential cellular pathways are considered
as critical for MM pathogenesis [31] and are associated with in vitro
anti-proliferative activity.
In particular, dysregulation of apoptosis has been demonstrated to
play a crucial role in DMPM chemoresistance [29]. For instance, we
found that DDX3Xwas one of the genes affected upon splicingmodula-
tion within the apoptotic pathway. This gene encodes a RNA helicase
involved in pre-mRNA splicing and apoptotic signaling and is mutated
in a subset of DMPM patients [4,7]. Interestingly, we identiﬁed a
PB-induced transcript variant of this gene lacking an in frame exon
(NM_001193417.2) which is most likely translated.In addition, heat-shock protein (HSP) family members exert impor-
tant anti-apoptotic roles [41] and seem to be up-regulated in MM [42].
Our analysis showed exon 3 skipping of the HSPH1 member, thus
adding additional evidence to the pro-apoptotic effect of SF3b
modulation.
Furthermore, previous literature [18] showed that targeting key
apoptotic pathways and genes such as survivin might be an effective
approach in DMPM therapy. We therefore encourage investigating AS
modulation in combination with standard HIPEC procedures.
In agreement with previous data on the impact of PB on cell cycle
regulation, we found PB-induced AS of CCNA2, which mediates cell
cycle progression through G2/M phase. However, we report the skip-
ping of exon 3 instead of exon 5, as found earlier by Effenberger et al.
[12].
Another relevant gene emerging from this analysis was CHEK1, af-
fected at the level of exon 3. This gene controls checkpoint-mediated
cell cycle arrest and activation of DNA repair and is a potential new tar-
get inMM treatment to overcome resistance to chemotherapy or radia-
tion [43].
Interestingly, epithelioid DMPM is characterized by epithelial-
mesenchymal transition (EMT) and mesenchymal-epithelial reverse
transition (MErT) features such as migration and cell-cell adhesion
[44]. Migration processes are controlled by transcription factors, tyro-
sine kinases and, as recently reviewed, also by alternatively spliced tran-
scripts such as ΔRON [33,34,45,46]. Our data clearly show that SF3b
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Fig. 5. Characterization of bioluminescent orthotopic DMPM in vivomodel. (A) Primary DMPM cells were transduced with Fm/GC vectors and tested for in vitro F-Luc activity before im-
plantation after two consecutive passages. The BLI signal was proportional to the number of cells. STO cells showed lower transduction efﬁciency compared toMesoII, whichwas also con-
ﬁrmed by in vivo F-Luc activity 7 days after cell implantation. (B) PET-CT and PET-MRI of MesoII model after [18F]-FDG intraocular administration. Tumors were localized throughout the
entire peritoneal and retro-peritoneal cavity (site of injection). (C) Clinicopathological features of the in vivo DMPMmodel. Macroscopic and histopathological (hematoxylin/eosin and
SF3B1 staining) examination of orthotopic tumor specimens. DMPMmice at Day 50 after cell implantation showed jaundice, cachexia and accumulation of ascitic ﬂuids in the peritoneal
cavity. Some animals presented high tumor load in proximity of the gastrointestinal tract which interferes with the normal digestive functions. SF3B1 staining showed high protein ex-
pression of the orthotopic tumor.
223R. Sciarrillo et al. / EBioMedicine 39 (2019) 215–225modulation impairs the splicing pattern of this variant and this effect is
reﬂected by reduction in cell migratory capacities in vitro.
Collectively, our in vitro assays show that the extent of SF3bmodula-
tion depends on the concentration of the compound and exposure
times. It is therefore important to design preclinical studies to identify
optimal therapeutic concentrations and clarify the role of pro-
apoptotic splice variants which mediate cytotoxic effects. In addition,
it is pivotal to characterize AS events in patient specimens compared
to matched healthy tissues. This may result in the identiﬁcation of
novel DMPM-speciﬁc splice variants and the development of more
targeted antitumor approaches. Furthermore, several studies suggest
that speciﬁc subtypes of cancers could be particularly sensitive to splic-
ingmodulation,most prominently those characterized by highMYC ex-
pression. Hsu and collaborators discovered that MYC-driven tumors
could be potentially vulnerable to spliceosome modulators because of
the increased transcription rates and the consequent engulfment of
the spliceosome machinery [47]. FISH analyses showed that mesotheli-
omas carry an ampliﬁcation of the 8q24 chromosomal region, which in-
cludes the c-MYC locus (frequencies vary between 15% [48] and 48% [5],
of which 64% occur in DMPM cases). Hence, future studies should deter-
mine whether these patients are hypersensitive to splicingmodulation.In line with the observation by Deraco et al. [28] that DMPM has
low proliferating activity and that a Ki-67 index above 5% is associ-
ated with dismal OS and PFS, our data show a signiﬁcant correlation
between Ki-67 values above 5% and signiﬁcantly shorted PFS. This
suggests that SF3b modulators may be effective especially in highly
aggressive cases due to their antiproliferative activity. Moreover, PB
was effective in vitro in cisplatin-resistant SCLC cells, irrespective of
their MYC status [49], and Lambert et al. [50] reported that cisplatin
and PB synergize in eradicating breast cancer cells. Therefore, splicing
modulation could constitute a promising option for chemotherapy-
resistant cases of DMPM and it may synergize with current standard
treatments. Ultimately, our data support the implementation of splic-
ing modulators into the clinic, since we showed that in vivo adminis-
tration of E7107 with four consecutive intraperitoneal injections
leads to complete eradication of the tumor masses in 50% of tested
animals throughout the study. In the light of this ﬁnding, we antici-
pate that locoregional administration of spliceosome modulators in
solid tumors may be more effective than intravenous delivery. This
might mitigate adverse events, especially those related to central ner-






















































Fig. 6.E7107 induced tumor regression and extended survival in an orthotopicDMPMmousemodel. (A) Experimental setup: bioluminescentDMPMcellswere injected into theperitoneal
cavity of immune deﬁcient mice and randomized after one week (6 animals per arm). E7107 was administered four times (two doses of 5 mg/kg and two doses of 2.5 mg/kg) and tumor
growth monitored twice a week until day 50, then every 3 weeks. (B) Representative BLI pictures at week 1, 2 and 6. BLI intensity scales were adjusted in respect to signal.
(C) Quantiﬁcation of BLI signal. Bars represent mean net pixel intensities ± SEM of each group. Statistical signiﬁcance between the two groups was achieved at Day 8 (*P = 0.001)
and persisted until termination of the experiment. (D) Kaplan-Meier analysis progression-free survival (PFS) of E7107 and vehicle-treated groups. P-value (****P b 0.0001) was
determined by the Log-rank (Mantel-Cox) test.
224 R. Sciarrillo et al. / EBioMedicine 39 (2019) 215–225In conclusion, novel therapeutic approaches are urgently needed for
DMPM, a rare disease characterized by poor survival rates and refracto-
riness to current therapeutic regimes. Our clinical data enrich the cur-
rent understanding of DMPM pathobiology and assign new prognostic
roles to SF3B1, which prompt validation studies and may be extended
to other spliceosome components. Finally, our in vitro and in vivo efﬁ-
cacy data support the rationale that drugs modulating the spliceosomal
activity and its downstream pathways may be applicable to future clin-
ical practice in DMPM.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2018.12.025.
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